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for early breast cancer includes a wide local excision with 
adjuvant radiotherapy. Clinical data suggest, that 
perturbations induced by surgery and the subsequent wound 
fluids, which are rich in cytokines and growth factors, may 
stimulate residual disease. Numerous studies demonstrate, 
that 90% of the local recurrence after surgery occur in the 
same quadrant as the primary cancer. It has been proposed, 
that cancer cells displaying the stem-like phenotype play a 
critical role in local recurrence, invasion and metastasis. One 
of the new possibilities in conservative cancer treatment is 
intraoperative radiotherapy (IORT). IORT delivers high dose 
of radiation as one single fraction at the time of surgery. It 
was previously reported, that IORT alters the 
microenvironment through the modulation of wound healing 
response. Thus we wondered, whether wound fluids can 
induce the enrichment of breast cancer stem cells 
phenotype in breast cancer cell lines and whether IORT 
plays inhibitory role in this process. 
 
Material and Methods: Wound fluids form patients which 
underwent IORT (IR-WF), as well as control group without 
radiotherapy treatment (WF), were collected week after the 
surgery. Three human cancer cell lines with different 
molecular status (basal – MDA-MB-468, luminal – MCF7 and 
Her2-positive – BT-474) were then incubated with wound 
fluids (WF, IR-WF) in complete culture medium (10%). After 
four days of incubation the cancer stem-cell phenotype was 
established. 
 
Results: Flow cytometry and RT-qPCR analysis revealed, that 
wound fluids from patients who received IORT decreased the 
phenotype of cancer-stem cells in the basal (MDA-MB-468) 
and luminal subtype (MCF7) of cancer cell lines compared to 
IORT-untreated patients. Such changes were not confirmed in 
HER2-posive cell line (BT-474). 
 
Conclusion: The surgical wound fluids from both groups (WF 
and IR-WF) affect the putative stem cell phenotype. In IR-WF 
group, the lower stem cell phenotype was observed 
compared to fluids harvested after surgery alone.  
This work was supported by NSC grant no UMO-
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Purpose or Objective: To determine the influence of two 
different injection schedules on the pimonidazole hypoxic 
fraction (pHF) in three different head and neck human 
squamous cell carcinoma (HNSCC) xenograft tumour models. 
 
 
Material and Methods: Three different HNSCC cell lines 
(FaDu, UT-SCC-5, UT-SCC-14) grown as xenograft tumours in 
nude mice (5 per cell line) where examined with different 
pimonidazole injection schedules. Either one single injection 
60 minutes prior to tumour excision (100 mg/kg BW i.p.) or 
three injections (each 33 mg/kg BW i.p.) starting 180 minutes 
before tumour excision with 60 minutes interval between 
injections. Both groups where given the perfusion marker 
Hoechst 33342 i.v. 1 minute prior to tumour excision. 
Tumours were snap frozen and consecutive central cross-
sections (10µm) where stained with antibodies for 
pimonidazole and CD31. Using image analysis the pHF and 
other parameters of the microenvironment were determined. 
 
Results: No statistically significant differences in pHF nor in 
visual staining patterns were observed after single versus 
multiple injections of pimonidazole (table and figure 1). 
Table 1: Mean values of the pHF [SD] in %.  
 
 
 
 
 
Fig. 1: pHF for the cell lines for single and multiple 
pimonidazole injection (mean value for pHF of the two 
analysed sections per tumour, closed symbols for single, open 
for multiple injections) 
 
Conclusion: In the HNSCC xenograft models investigated here 
pimonidazole detects predominantly chronic hypoxia. 
Assessment of cycling hypoxia requires alternative methods. 
Our data suggest that cycling hypoxia occurs either at a low 
level in our models or that hypoxia cycles so rapid that 
pimonidazole cannot bind sufficiently or cycling hypoxia 
levels are not low enough for pimonidazole reduction. 
 
Electronic Poster: Radiobiology track: Normal tissue 
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Purpose or Objective: Radiotherapy toxicity is related to 
oxidative stress-mediated endothelial dysfunction. Here, we 
investigated on radioprotective properties of Vitamin D 
(Vit.D) on human endothelial cells (HUVEC). 
 
Material and Methods: HUVEC, pre-treated with Vit.D, were 
exposed to ionizing radiation (IR): ROS production, cellular 
viability, apoptosis, senescence and western blot for protein 
detection were performed. The role of MAPKs pathway was 
investigated by using U0126 (10 μM) MEKs/ERKs-, SB203580 
(2.5 μM) p38-inhibitor or by over/expressing MKK6 p38-
upstream activator. 
 
Results: Vit.D reduced IR-induced ROS production protecting 
proliferating and quiescent HUVEC from cellular apoptosis or 
senescence, respectively, by regulating MAPKs pathways. In 
proliferating HUVEC, Vit.D prevented IR-induced apoptosis by 
activating ERKs while in quiescent HUVEC counteracted IR-
induced senescence by inhibiting the p38-IR-induced 
activation. MEKs&ERKs inhibition in proliferating or 
MKK6/mediated p38 activation in quiescent HUVEC, 
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respectively, reverted anti-apoptotic or anti-senescent Vit.D 
properties. SirT1 protein expression levels were up-regulated 
by Vit.D. ERKs inhibition blocked Vit.D-induced SirT1 protein 
up-regulation in proliferating cells. In quiescent HUVEC cells, 
p38 inhibition counteracted the IR-induced SirT1 protein 
down-regulation, while MKK6 transfection abrogated the 
Vit.D positive effects on SirT1 protein levels after irradiation. 
SirT1 inhibition by sirtinol blocked the Vit.D radioprotective 
effects. 
 
Conclusion: Vit.D protects HUVEC from IR induced/oxidative 
stress by positively regulating the MAPKs/SirT1 axis. 
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Purpose or Objective: Trials of amifostine in patients with 
advanced non-small cell lung cancer (NSCLC) receiving 
chemoradiotherapy (CRT) or radiotherapy (RT) alone report 
varying treatment-related toxicity. A review and meta-
analysis was conducted to examine amifostine’s effect on 
toxicity and efficacy of CRT or RT alone in such patients. 
 
Material and Methods: Searches of electronic databases 
yielded 16 eligible trials comprising 1057 patients. Data 
extracted from randomised and non-randomised trials were 
compiled in a review; results of randomised trials were 
pooled and using meta-analyses to estimate the effect of 
amifostine on treatment toxicity and efficacy.  
 
Results: Amifostine reduced the risk of >Grade 2 acute 
oesophagitis by 26% (risk ratio [RR], 0.74; 95% confidence 
interval [CI], 0.65-0.86; p<0.0001) and the risk of acute 
pulmonary toxicity by 44% (RR, 0.56; 95%CI, 0.41-0.75; 
p=0.0001). Amifostine did not alter risk of late pulmonary 
toxicity (RR, 0.84; 95% CI, 0.65-1.08; p=0.17). Risk of 
complete response was unchanged (RR, 1.64; 95% CI, 0.99-
2.73; p=0.06), partial response was unchanged (RR, 0.92; 95% 
CI, 0.73-1.16; p=0.48). Statistical heterogeneity was high for 
toxicity but low for response. Non-randomised trials reported 
varying incidence of toxicities and survival/response. Studies 
were medium-high quality. 
 
Conclusion: Statistical heterogeneity casts doubt over 
amifostine’s efficacy in this setting, despite evidence of 
decreased incidence of acute oesophageal and pulmonary 
toxicity but not late pulmonary toxicity. Amifostine did not 
compromise CRT or RT efficacy.  
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Purpose or Objective: It is well known that proton therapy 
generates a small but significant exposure to scattered 
neutrons. The success of paediatric proton treatments leads 
to a concern about second cancers arising in later life from 
the neutron exposure. However there are difficulties involved 
with estimating the risk from exposure to neutrons. The usual 
approach is through the concept of relative biological 
effectiveness (RBE) of neutrons compared to photons, since 
the risk from photon exposure is much better known (ICRP 
Publication 103. Ann. ICRP 37 (2-4), 2007) The RBE for 
neutrons has been evaluated using cellular and animal 
models. But this causes uncertainty when applying the 
method to humans. The ANDANTE project 
(http://www.andanteproject.eu/) has investigated the 
relative risk of cancer from neutrons compared to photons in 
the context of proton therapy, using three different 
disciplines in parallel.  
 
Material and Methods: Physics: Charged particle spectra 
generated by both neutron and photon beams were 
characterised using Monte Carlo simulation and 
measurements. A track structure model was used to model 
the formation of complex lesions in DNA from the different 
spectra as an indicator of relative likelihood of cancer 
induction. A method was developed for reconstructing the 
scattered neutron doses outside the treatment volume during 
proton therapy, using available clinical data, in order to be 
able to predict second cancer risks. Stem cell radiobiology: 
Stem cells from thyroid, salivary gland, and breast tissue 
were given well characterised exposures to both broad- and 
narrow-spectrum neutron beams, and to 200 kV X-rays. The 
relative risk of damage from neutrons compared to photons 
was estimated using a number of endpoints. Part of the cell 
population was transplanted into mice. Detailed 
histopathological and molecular investigations were 
performed looking for pre-malignant lesions and signs of 
malignancy. Epidemiology: The results from the track 
structure modelling and stem cell experiments were 
combined to generate a relative risk model. Dose 
reconstruction and data analysis tools were developed for a 
multi-centre prospective epidemiological study using data 
from paediatric proton therapy treatments, which will test 
the relative risk model. The project has made initial plans for 
the study as a collaboration between centres in Europe and 
the USA. 
 
Results: The track structure model reproduced the peak in 
relative risk between neutrons and photons at a neutron 
energy of around 1 MeV, similar to the ICRP model. The stem 
cell experiments successfully demonstrated a new 
methodology, but did not provide conclusive evidence to 
contradict the ICRP model. The feasibility of a prospective 
epidemiological study was demonstrated. 
 
Conclusion: The results from the ANDANTE project do not 
contradict ICRP. In the longer term, the prospective study 
will provide greater certainty on the RBE for neutrons and 
how this applies to humans receiving proton therapy. 
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Purpose or Objective: Radiation-induced fibrosis is a delayed 
complication of radiotherapy often associated with chronic 
inflammatory process and macrophage infiltration. 
Nowadays, macrophages are suggested to be important 
cellular contributors to fibrogenic process, but their 
implication in the context of RIF is not well known. 
 
Material and Methods: To investigate the role of 
macrophages in RIF we have used a classical experimental 
model of lung fibrosis developed in C57Bl/6 mice after 16Gy 
thorax-IR. We then profiled both alveolar macrophages (AM) 
and interstitial macrophages (IM) during the various steps of 
the fibrogenic process. 
 
Results: We confirmed the fact that total lung irradiation at 
16Gy (IR) induces an interstitial fibrosis associated with 
delayed recruitment of pulmonary macrophages.  
We found a transient depletion of AM associated with 
cytokine secretion during the acute post-IR phase (15 days), 
followed by an active repopulation and an enhanced number 
of AM during the late post-IR phase (20 weeks). Interestingly, 
AM were mostly recruited from the bone marrow and exhibit 
a hybrid polarization (M1/M2) associated with up-regulation 
of Th1 and Th2 cytokines. The number of M2-polarized IM 
significantly increased during the late time points after 
irradiation and a down-regulation of Th1 cytokine was 
measured in tissue lysate. These results suggest a differential 
contribution of hybrid AM vs M2-IM to fibrogenesis. 
Interestingly, in contrast to activated hybrid AM, activated 
